# A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

> **NCT06345794** · PHASE1 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4100511 (DC-853)
- **DRUG:** Itraconazole
- **DRUG:** Fluconazole
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT06345794
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-03
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345794, "A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06345794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*